Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical issues in antibody design

K A Chester1, R E Hawkins

  • 1Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, UK.

Trends in Biotechnology
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.

Journal for immunotherapy of cancer·2016
Same author

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

British journal of cancer·2015
Same author

Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma.

British journal of cancer·2015
Same author

CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.

Clinical and experimental immunology·2013
Same author

Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells.

Gene therapy·2011
Same author

Site-specific polysialylation of an antitumor single-chain Fv fragment.

Bioconjugate chemistry·2009

Engineered antibodies offer improved therapeutic potential by enhancing affinity, reducing immunogenicity, and enabling novel functions. This review explores these advanced antibody therapeutics and their application in cancer treatment.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Antibody engineering allows for the creation of modified antibodies with enhanced therapeutic properties.
  • These modifications include reduced immunogenicity, improved binding affinity, altered size, increased avidity, and novel effector functions.

Purpose of the Study:

  • To review advancements in antibody-based therapeutic molecules.
  • To examine the role of these improved antibodies in cancer therapy.

Main Methods:

  • Review of current literature on antibody gene cloning and expression.
  • Analysis of antibody engineering techniques and their clinical applications.

Main Results:

  • Engineered antibodies demonstrate significant improvements in key characteristics like affinity and immunogenicity.

Related Experiment Videos

  • Novel effector functions can be introduced to enhance therapeutic efficacy.

    • Conclusions:

    • Optimized antibody design is crucial for effective clinical applications in cancer therapy.
    • Advanced antibody therapeutics represent a promising frontier in oncology treatment.